175 related articles for article (PubMed ID: 36105269)
1. Cannabidiol Effect on Cue-Induced Craving for Individuals with Opioid Use Disorder Treated with Buprenorphine: A Small Proof-of-Concept Open-Label Study.
Suzuki J; Martin B; Prostko S; Chai PR; Weiss RD
Integr Med Rep; 2022 Aug; 1(1):157-163. PubMed ID: 36105269
[TBL] [Abstract][Full Text] [Related]
2. Impact of cannabidiol on reward- and stress-related neurocognitive processes among individuals with opioid use disorder: A pilot, double-blind, placebo-controlled, randomized cross-over trial.
Suzuki J; Prostko S; Szpak V; Chai PR; Spagnolo PA; Tenenbaum RE; Ahmed S; Weiss RD
Front Psychiatry; 2023; 14():1155984. PubMed ID: 37065899
[TBL] [Abstract][Full Text] [Related]
3. Cannabidiol for the Reduction of Cue-Induced Craving and Anxiety in Drug-Abstinent Individuals With Heroin Use Disorder: A Double-Blind Randomized Placebo-Controlled Trial.
Hurd YL; Spriggs S; Alishayev J; Winkel G; Gurgov K; Kudrich C; Oprescu AM; Salsitz E
Am J Psychiatry; 2019 Nov; 176(11):911-922. PubMed ID: 31109198
[TBL] [Abstract][Full Text] [Related]
4. Adjunctive Management of Opioid Withdrawal with the Nonopioid Medication Cannabidiol.
Kudrich C; Hurd YL; Salsitz E; Wang AL
Cannabis Cannabinoid Res; 2022 Oct; 7(5):569-581. PubMed ID: 34678050
[No Abstract] [Full Text] [Related]
5. Cannabidiol as a treatment for craving and relapse in individuals with cocaine use disorder: a randomized placebo-controlled trial.
Mongeau-Pérusse V; Brissette S; Bruneau J; Conrod P; Dubreucq S; Gazil G; Stip E; Jutras-Aswad D
Addiction; 2021 Sep; 116(9):2431-2442. PubMed ID: 33464660
[TBL] [Abstract][Full Text] [Related]
6. Association of PDYN 68-bp VNTR polymorphism with sublingual buprenorphine/naloxone treatment and with opioid or alcohol use disorder: Effect on craving, depression, anxiety and age onset of first use.
Kaya-Akyüzlü D; Özkan-Kotiloğlu S; Yalçın-Şahiner Ş; Ağtaş-Ertan E; Özgür-İlhan İ
Eur J Pharmacol; 2022 Apr; 921():174862. PubMed ID: 35271823
[TBL] [Abstract][Full Text] [Related]
7. The role of withdrawal in mesocorticolimbic drug cue reactivity in opioid use disorder.
Shi Z; Jagannathan K; Padley JH; Wang AL; Fairchild VP; O'Brien CP; Childress AR; Langleben DD
Addict Biol; 2021 Jul; 26(4):e12977. PubMed ID: 33098179
[TBL] [Abstract][Full Text] [Related]
8. Beneficial Effects of Opioid Rotation to Buprenorphine/Naloxone on Opioid Misuse, Craving, Mental Health, and Pain Control in Chronic Non-Cancer Pain Patients with Opioid Use Disorder.
Schellekens AFA; Veldman SE; Suranto ESD; van Rijswijk SM; van der Wal SEI; Schene AH; van Beek MHCT
J Clin Med; 2021 Aug; 10(16):. PubMed ID: 34442024
[TBL] [Abstract][Full Text] [Related]
9. Effect of Buprenorphine Weekly Depot (CAM2038) and Hydromorphone Blockade in Individuals With Opioid Use Disorder: A Randomized Clinical Trial.
Walsh SL; Comer SD; Lofwall MR; Vince B; Levy-Cooperman N; Kelsh D; Coe MA; Jones JD; Nuzzo PA; Tiberg F; Sheldon B; Kim S
JAMA Psychiatry; 2017 Sep; 74(9):894-902. PubMed ID: 28655025
[TBL] [Abstract][Full Text] [Related]
10. Extended-release pharmacotherapy for opioid use disorder (EXPO): protocol for an open-label randomised controlled trial of the effectiveness and cost-effectiveness of injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone.
Marsden J; Kelleher M; Hoare Z; Hughes D; Bisla J; Cape A; Cowden F; Day E; Dewhurst J; Evans R; Hearn A; Kelly J; Lowry N; McCusker M; Murphy C; Murray R; Myton T; Quarshie S; Scott G; Turner S; Vanderwaal R; Wareham A; Gilvarry E; Mitcheson L
Trials; 2022 Aug; 23(1):697. PubMed ID: 35986418
[TBL] [Abstract][Full Text] [Related]
11. A Prescription Digital Therapeutic to Support Unsupervised Buprenorphine Initiation for Patients With Opioid Use Disorder: Protocol for a Proof-of-Concept Study.
Luderer H; Enman N; Gerwien R; Braun S; McStocker S; Xiong X; Koebele C; Cannon C; Glass J; Maricich Y
JMIR Res Protoc; 2023 Jan; 12():e43122. PubMed ID: 36662568
[TBL] [Abstract][Full Text] [Related]
12. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
Rog DJ; Nurmikko TJ; Young CA
Clin Ther; 2007 Sep; 29(9):2068-79. PubMed ID: 18035205
[TBL] [Abstract][Full Text] [Related]
13. A case report illustrating the effects of repetitive transcranial magnetic stimulation on cue-induced craving in an individual with opioid and cocaine use disorder.
Mahoney JJ; Marshalek PJ; Rezai AR; Lander LR; Berry JH; Haut MW
Exp Clin Psychopharmacol; 2020 Feb; 28(1):1-5. PubMed ID: 31647279
[TBL] [Abstract][Full Text] [Related]
14. Don't Fear the Reefer-Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy.
Perry MS
Epilepsy Curr; 2019; 19(2):93-95. PubMed ID: 30955420
[TBL] [Abstract][Full Text] [Related]
15. Neurocognitive, psychiatric, and substance use characteristics in a diverse sample of persons with OUD who are starting methadone or buprenorphine/naloxone in opioid treatment programs.
Scott TM; Arnsten J; Olsen JP; Arias F; Cunningham CO; Rivera Mindt M
Addict Sci Clin Pract; 2021 Oct; 16(1):64. PubMed ID: 34689841
[TBL] [Abstract][Full Text] [Related]
16. Rationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veterans.
Petrakis I; Springer SA; Davis C; Ralevski E; Gu L; Lew R; Hermos J; Nuite M; Gordon AJ; Kosten TR; Nunes EV; Rosenheck R; Saxon AJ; Swift R; Goldberg A; Ringer R; Ferguson R
Addict Sci Clin Pract; 2022 Jan; 17(1):6. PubMed ID: 35101115
[TBL] [Abstract][Full Text] [Related]
17. Laboratory-induced stress and craving predict opioid use during follow-up among individuals with prescription opioid use disorder.
Saraiya TC; Jarnecke AM; Jones J; Brown DG; Brady KT; Back SE
Drug Alcohol Depend; 2021 Aug; 225():108755. PubMed ID: 34052686
[TBL] [Abstract][Full Text] [Related]
18. Sleep moderates the relationship between stress and craving in individuals with opioid use disorder.
Teeters JB; Jones JL; Jarnecke AM; Back SE
Exp Clin Psychopharmacol; 2021 Aug; 29(4):418-426. PubMed ID: 32297784
[TBL] [Abstract][Full Text] [Related]
19. The Therapeutic Potential of Cannabidiol in Revolutionising Opioid Use Disorder Management.
Le K; Au J; Hua J; Le KDR
Cureus; 2023 Dec; 15(12):e50634. PubMed ID: 38226097
[TBL] [Abstract][Full Text] [Related]
20. Cannabidiol reverses attentional bias to cigarette cues in a human experimental model of tobacco withdrawal.
Hindocha C; Freeman TP; Grabski M; Stroud JB; Crudgington H; Davies AC; Das RK; Lawn W; Morgan CJA; Curran HV
Addiction; 2018 May; 113(9):1696-705. PubMed ID: 29714034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
